Health Care & Life Sciences » Biotechnology | bioMmune Technologies Inc.

bioMmune Technologies Inc. | Balance Sheet

Fiscal year is December-November. All values CAD Thousands.
2015
2016
2017
2018
Cash & Short Term Investments
998.20
1,028.10
114.70
3,644.60
Total Accounts Receivable
22.80
18.30
17.20
13.70
Other Current Assets
99.30
44.30
72.30
109.90
Total Current Assets
1,120.30
1,090.70
204.20
3,768.20
Net Property, Plant & Equipment
1.80
3.00
56.00
49.90
Intangible Assets
956.30
870.50
784.70
-
Total Assets
2,078.30
1,964.20
1,044.90
3,818.10
Other Current Liabilities
131.10
113.10
85.20
Total Current Liabilities
131.10
113.10
85.20
Total Liabilities
131.10
113.10
85.20
Common Equity (Total)
1,947.20
1,851.10
959.60
Total Shareholders' Equity
1,947.20
1,851.10
959.60
Total Equity
1,947.20
1,851.10
959.60
Liabilities & Shareholders' Equity
2,078.30
1,964.20
1,044.90

About bioMmune Technologies

View Profile
Address
400 Burrard Street
Vancouver British Columbia V6C 3A6
Canada
Employees -
Website http://www.pascalbiosciences.com
Updated 07/08/2019
Pascal Biosciences Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: Major Histocompatibility Complex I (MHC I), CD74 and Calcium Channel Blockers. The MHC I technology is a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells where the fragments are then exposed to the immune system's T cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.